David Risinger
Stock Analyst at Leerink Partners
(3.87)
# 771
Out of 4,479 analysts
97
Total ratings
70.77%
Success rate
19.93%
Average return
Main Sectors:
29 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio | Initiates: Outperform | $47 | $24.61 | +90.98% | 1 | Apr 16, 2024 | |
| AMGN Amgen | Upgrades: Outperform | $267 → $318 | $311.01 | +2.25% | 4 | Oct 11, 2023 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $6 → $11 | $8.80 | +25.00% | 2 | Aug 15, 2023 | |
| BMY Bristol-Myers Squibb Company | Initiates: Market Perform | $66 | $41.30 | +59.81% | 3 | Jul 10, 2023 | |
| LLY Eli Lilly | Maintains: Outperform | $410 → $458 | $914.37 | -49.91% | 13 | May 1, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $834 → $976 | $1,057.02 | -7.66% | 6 | Mar 27, 2023 | |
| HALO Halozyme Therapeutics | Downgrades: Market Perform | $42 | $52.02 | -19.26% | 3 | Mar 16, 2023 | |
| ABBV AbbVie | Upgrades: Market Perform | $135 → $153 | $170.37 | -10.20% | 4 | Feb 10, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $374 → $365 | $471.25 | -22.55% | 3 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Market Perform | $81 → $91 | $68.64 | +32.58% | 3 | Feb 3, 2023 | |
| PFE Pfizer | Maintains: Market Perform | $49 → $48 | $28.22 | +70.09% | 9 | Feb 1, 2023 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $194 → $186 | $146.44 | +27.01% | 2 | Jan 20, 2023 | |
| ROIV Roivant Sciences | Maintains: Outperform | $8 → $10 | $10.83 | -7.66% | 4 | Dec 19, 2022 | |
| PCVX Vaxcyte | Initiates: Outperform | $60 | $76.94 | -22.02% | 1 | Dec 16, 2022 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $12 → $14 | $8.52 | +64.32% | 2 | Nov 17, 2022 | |
| RDUS Radius Health | Maintains: Market Perform | $7 → $10 | $15.29 | -34.60% | 2 | Jun 24, 2022 | |
| HLVX HilleVax | Initiates: Outperform | $30 | $14.42 | +108.04% | 1 | May 24, 2022 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $35 → $37 | $20.31 | +82.18% | 2 | Feb 22, 2022 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Equal-Weight | n/a | $106.47 | - | 3 | Apr 1, 2021 | |
| VTRS Viatris | Maintains: Equal-Weight | n/a | $10.59 | - | 1 | Mar 10, 2021 | |
| PRGO Perrigo Company | Maintains: Equal-Weight | n/a | $26.25 | - | 5 | Mar 5, 2021 | |
| BHC Bausch Health Companies | Maintains: Equal-Weight | n/a | $7.09 | - | 1 | Feb 26, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | n/a | $14.10 | - | 2 | Aug 20, 2020 | |
| RPRX Royalty Pharma | Initiates: Equal-Weight | n/a | $26.19 | - | 1 | Jul 13, 2020 | |
| ZTS Zoetis | Maintains: Equal-Weight | n/a | $172.58 | - | 2 | Apr 2, 2020 | |
| TEVA Teva Pharmaceutical | Maintains: Underweight | n/a | $16.34 | - | 9 | Apr 2, 2020 | |
| MRK Merck & Co. | Maintains: Overweight | n/a | $127.90 | - | 6 | Apr 2, 2020 | |
| ALKS Alkermes | Maintains: Equal-Weight | n/a | $24.39 | - | 1 | Apr 2, 2020 | |
| AMRX Amneal Pharmaceuticals | Downgrades: Equal-Weight | n/a | $6.42 | - | 1 | Dec 14, 2018 |
AnaptysBio
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $24.61
Upside: +90.98%
Amgen
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $311.01
Upside: +2.25%
Centessa Pharmaceuticals
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $8.80
Upside: +25.00%
Bristol-Myers Squibb Company
Jul 10, 2023
Initiates: Market Perform
Price Target: $66
Current: $41.30
Upside: +59.81%
Eli Lilly
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $914.37
Upside: -49.91%
Regeneron Pharmaceuticals
Mar 27, 2023
Upgrades: Outperform
Price Target: $834 → $976
Current: $1,057.02
Upside: -7.66%
Halozyme Therapeutics
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $52.02
Upside: -19.26%
AbbVie
Feb 10, 2023
Upgrades: Market Perform
Price Target: $135 → $153
Current: $170.37
Upside: -10.20%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Outperform
Price Target: $374 → $365
Current: $471.25
Upside: -22.55%
Gilead Sciences
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $68.64
Upside: +32.58%
Pfizer
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $28.22
Upside: +70.09%
Johnson & Johnson
Jan 20, 2023
Maintains: Outperform
Price Target: $194 → $186
Current: $146.44
Upside: +27.01%
Roivant Sciences
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $10.83
Upside: -7.66%
Vaxcyte
Dec 16, 2022
Initiates: Outperform
Price Target: $60
Current: $76.94
Upside: -22.02%
Theravance Biopharma
Nov 17, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $8.52
Upside: +64.32%
Radius Health
Jun 24, 2022
Maintains: Market Perform
Price Target: $7 → $10
Current: $15.29
Upside: -34.60%
HilleVax
May 24, 2022
Initiates: Outperform
Price Target: $30
Current: $14.42
Upside: +108.04%
Organon & Co.
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $20.31
Upside: +82.18%
Jazz Pharmaceuticals
Apr 1, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $106.47
Upside: -
Viatris
Mar 10, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $10.59
Upside: -
Perrigo Company
Mar 5, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $26.25
Upside: -
Bausch Health Companies
Feb 26, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $7.09
Upside: -
Elanco Animal Health
Aug 20, 2020
Upgrades: Overweight
Price Target: n/a
Current: $14.10
Upside: -
Royalty Pharma
Jul 13, 2020
Initiates: Equal-Weight
Price Target: n/a
Current: $26.19
Upside: -
Zoetis
Apr 2, 2020
Maintains: Equal-Weight
Price Target: n/a
Current: $172.58
Upside: -
Teva Pharmaceutical
Apr 2, 2020
Maintains: Underweight
Price Target: n/a
Current: $16.34
Upside: -
Merck & Co.
Apr 2, 2020
Maintains: Overweight
Price Target: n/a
Current: $127.90
Upside: -
Alkermes
Apr 2, 2020
Maintains: Equal-Weight
Price Target: n/a
Current: $24.39
Upside: -
Amneal Pharmaceuticals
Dec 14, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $6.42
Upside: -